Sirius Therapeutics, a San Diego, CA-based developer of siRNA therapeutics for patients with chronic diseases, raised nearly $50M in Series B2 funding.
The round was led by an undisclosed investor, with participation from BioTrack Capital, and existing investors OrbiMed, Creacion Ventures, and Hankang Capital.
The company intends to use the funds to advance clinical development of its new siRNA therapeutics for cardiometabolic disorders and the growth of its new RNA delivery technologies.
Founded in 2021 and led by CEO Dr. Qunsheng Ji, Sirius develops siRNA therapeutics for patients with chronic diseases globally. It established an innovation center in the United States and a translational medicine center in China dedicated to solutions for the treatment and management of chronic diseases.
The company has raised nearly $150M to date.
FinSMEs
10/05/2025